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S U M M A R Y
Background: The effect of time of the ﬁrst antimicrobial dose (TFAD) on the outcomes of community-
acquired pneumonia (CAP) remains a controversy.
Methods: This was an observational, retrospective study of consecutive adult patients hospitalized with
CAP. TFAD was deﬁned as the time in hours from arrival at the emergency department to the intravenous
infusion of antimicrobial. All patients received appropriate antibiotic therapy according to available
Infectious Diseases Society of America/American Thoracic Society guidelines during the time of our
study. Multivariable analysis and a propensity score adjusted methodology were used to measure the
association of TFAD with mortality, time to clinical stability (TCS), and length of stay in the hospital
(LOS).
Results: Data of 372 patients with CAP were studied. A total 29 (8.4%) patients died within 30 days of
hospitalization. Our propensity-adjusted logistic regression model did not show a signiﬁcant association
between TFAD and mortality (p = 0.148). Patients who died received antimicrobials signiﬁcantly earlier
than survivors: 5.7 h vs. 7.5 h, respectively (p = 0.04). The LOS and TCS were not signiﬁcantly affected by
the TFAD; the LOS hazard ratio was 0.996 (95% conﬁdence interval 0.97–1.02; p = 0.774) and the TCS
hazard ratio was 1.01 (95% conﬁdence interval 0.98–1.03; p = 0.604).
Conclusions: TFAD does not seem to be associated with the clinical outcome of patients with CAP. Early
TFAD should be considered as an important marker of optimal care of patients with CAP rather than as a
factor predicting outcomes.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Community-acquired pneumonia (CAP) is the leading cause of
death from infectious diseases in most developed countries.1–3
Due to the burden of CAP on morbidity and mortality, healthcare
providers must adopt practices focused on improving outcomes.
A key measure to achieve this target is to optimize the practice of
antimicrobial usage. During the past decades, increasing evi-
dence has strengthened the recommendations of guidelines
concerning risk factor analysis and appropriate antimicrobial* Corresponding author.
E-mail address: jbordon@provhosp.org (J. Bordon).
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http://dx.doi.org/10.1016/j.ijid.2012.09.021practices.2,3 There is a logical assumption that early antimicrobial
treatment leads to favorable outcomes in CAP, while delayed
antimicrobial therapy leads to poor outcomes. The early
administration of antimicrobial therapy is expected to be
effective in those with an early diagnosis of bacterial pneumonia
and in cases with an effective host response. This assumption has
not been consistently validated and it has been reported that
practices targeting early antimicrobial administration increase
the risk of treating cases of suspected pneumonia that are
subsequently conﬁrmed not to be.4,5
The effect of time of the ﬁrst antimicrobial dose (TFAD) on the
outcome of CAP remains controversial. Two retrospective studies
of Medicare beneﬁciaries demonstrated signiﬁcantly lower mor-
tality among patients who received early antibiotic therapy.6,7ses. Published by Elsevier Ltd. All rights reserved.
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evaluate the correlation of the TFAD with clinical outcomes of
patients with CAP, our study examined a cohort of patients with
CAP hospitalized at the Louisville Veterans Affairs Medical Center
and measured the associations of TFAD with hospital mortality,
TCS, and LOS adjusted by propensity models.
2. Materials and methods
This was an observational, retrospective study of consecutive
adult patients hospitalized with CAP at the Veterans Affairs
Medical Center of Louisville, Kentucky, USA, from June 2001
through March 2006. These patients were enrolled in the
Community-Acquired Pneumonia Organization (CAPO) cohort
study. The study was approved by the Veterans Affairs Medical
Center Institutional Review Board. Data on patient demographic
characteristics, risk factors for coronary artery disease, medical co-
morbidities, clinical and laboratory variables, radiographic ﬁnd-
ings, electrocardiogram ﬁndings, severity of disease determined on
the basis of the pneumonia severity index (PSI) score and the CRB-
65 score, microbiological data, time to clinical stability (TCS),
duration of hospital stay, clinical failure, mortality at hospital
discharge, mortality at 30 days, and acute myocardial infarction
(AMI) on hospital admission or during hospital stay were extracted
for this study. Copies of the study protocol and data collection form
are available at the study web site (http://www.caposite.com).12
2.1. Study deﬁnitions
CAP was deﬁned as the presence of a new pulmonary inﬁltrate
on chest radiograph at the time of hospital admission and either a
new or increased cough with or without sputum production, an
abnormal temperature (<35.6 8C or >37.8 8C), or an abnormal
serum leukocyte count (e.g., leukocytosis, left shift, or leukopenia).
The severity of CAP at the time of hospitalization was measured
using the PSI score. Severe CAP at the time of hospital admission
was deﬁned as the need for admission into the intensive care unit
(ICU). Clinical stability was deﬁned as an absence of fever,
improved signs and symptoms associated with CAP, and improved
leukocyte count. The time of emergency department (ED) arrival
was the time recorded in the patient ED registration. The time of
the ﬁrst antibiotic dose was determined from the nurse’s notes on
timing of the antibiotic administration. TFAD was deﬁned as a
continuous variable, indicating the time in hours from arrival to
the ED to intravenous (IV) infusion of antimicrobial. TFAD were
grouped as: <2 h, >2 h to <4 h, >4 h to <8 h, and >8 h. Patients
who received oral or IV antimicrobial therapy before arrival at the
ED, or 24 h after arriving at the ED, were excluded.
All patients received appropriate antibiotic therapy according
to available Infectious Diseases Society of America/American
Thoracic Society (IDSA/ATS) guidelines during the time of our
study.
2.2. Statistical analysis
Baseline characteristics of patients who died versus those who
survived were compared using the Chi-square or Fisher’s exact
tests for categorical variables and the Mann–Whitney U-test for
continuous variables. To examine the adjusted effect of antimi-
crobial timing on the outcomes of mortality, TCS, and length of stay
in the hospital (LOS), a propensity score adjustment methodology
was used. After creation of the propensity score, a logistic
regression model was used to examine the propensity-adjusted
effect of antimicrobial timing on mortality, while Cox proportional
hazards regression models were used for TCS and LOS. p-Values of0.05 were considered statistically signiﬁcant. SAS v9.2 (SAS Inc.,
Cary, NC, USA) was used for all analyses.
Variables included in the propensity score are of known
importance in the medical literature and deemed clinically relevant
potential confounding variables. Propensity score adjustment was
used to control the effects of confounding factors on TFAD and
outcomes of CAP.13 This analysis controlled for the following
variables using a propensity-adjusted logistic regression model: age,
platelet count, albumin, creatinine, diabetes mellitus, arterial
hypertension, corticosteroids, blood urea nitrogen (BUN), AMI,
gender, ICU admission, respiratory rate, blood pressure (systolic
(SBP) and diastolic), sodium, oxygen saturation, heart rate, nursing
home residence, presence of existing diagnoses like cancer, liver
disease, congestive heart failure (CHF), cerebrovascular accidents
(CVA), renal disease, AMS, chronic obstructive pulmonary disease
(COPD), and HIV infection, and indicators of complex pneumonia
like multilobar inﬁltrates, pleural effusion, and cavitary lesions.
3. Results
A total 372 patients with CAP were enrolled during the study
period. The main characteristics of the study population are
summarized in Table 1. A total 29 (8.4%) patients died within 30
days after hospitalization. The main characteristics of patients are
summarized in Table 1. The patients who died tended to be older
than survivors: mean age 78 years vs. 68.9 years, respectively. A
total of 67 (18.0%) patients were admitted to the ICU.
The mortality of patients admitted to the ICU was 10.4%. ICU
admissions were not signiﬁcantly different between those who
died and those who survived. AMS was reported in 33 (8.9%)
patients and four of them (12.1%) died. AMS was not signiﬁcantly
different among those who died and those who survived.
Neoplastic disease, CHF, AMI, SBP less than 90 mmHg, presence
of pleural effusion, arterial blood pH <7.35, BUN >30 mg/dl, and
PSI classes IV and V were signiﬁcantly greater among those who
died. PSI classes IV and V were reported in 25 (86.2%) patients who
died. However, a CRB-65 score of 2–4 was present in only six
(20.7%) patients who died. There were statistically signiﬁcant
differences in PSI class IV and V scores between the two groups,
though this was not the case for a CRB-65 score of 2–4.
Our propensity-adjusted logistic regression model did not show
any signiﬁcant association between TFAD with the risk of mortality
(p = 0.148) (Fig. 1). Similarly the propensity-adjusted logistic
regression model corrected by eliminating nursing patients and
patients who died within 48 h of hospitalization revealed no
signiﬁcant association between TFAD and the risk of mortality
p = 0.113 (Fig. 2); nor for patients admitted to ICU p=0.348 (Fig. 3).
Patients who died received antimicrobials signiﬁcant earlier than
survivors: 5.7 h versus 7.5 h, respectively (p = 0.04). Among
survivors, the mean TCS was 3.6 days (SD 2.5) for antimicrobials
given in less than 4 h, mean: 3.1 days (SD 2.3) for antimicrobials
given between 4 and 8 h, and mean: 2.9 days (SD 2.2) for
antimicrobials given after 8 h. In the same group, the mean LOS
was 5.9 days (SD 3.9) for antimicrobials at <4 h, mean: 5.1 days (SD
3.5) for antimicrobials given between 4 and 8 h, and mean: 5.6 days
(SD: 4.1) for antimicrobials given after 8 h. The LOS and TCS were not
signiﬁcantly affected by the TFAD. The LOS hazard ratio was 0.996
(95% conﬁdence interval 0.97–1.02; p = 0.774) and the TCS hazard
ratio was 1.01 (95% conﬁdence interval 0.98–1.03; p = 0.604).
4. Discussion
Our study measured the correlation of TFAD with mortality,
TCS, and LOS of patients with CAP using a propensity-adjusted
model controlling for 36 variables. Our cohort study results did not
show any correlation of TFAD with the mortality, TCS, or LOS of
Table 1
Characteristics of patients with CAP who died and survived in relation to the time of ﬁrst antimicrobial dose
Patient characteristics Variable Died n = 29 Survived n = 343 p-Value
Demographic information
Age, years, mean (SD) 78.0 (8.4) 68.9 (12.4) <0.001
Male gender 26 (89.7) 338 (98.5) 0.002
Co-morbidities
Neoplastic disease 7 (24.1) 35 (10.2) 0.023
Congestive heart failure 12 (41.4) 82 (23.9) 0.038
Renal disease 8 (27.6) 51 (14.9) 0.072
Liver disease 1 (3.4) 9 (2.6) 0.792
Acute myocardial infarction 5 (17.2) 20 (5.8) 0.018
Cerebrovascular accident 3 (10.3) 40 (11.7) 0.831
Chronic obstructive pulmonary disease 14 (48.3) 160 (46.6) 0.866
Diabetes mellitus 10 (34.5) 122 (35.6) 0.907
Arterial hypertension 24 (82.8) 236 (68.8) 0.116
HIV infection 0 (0) 2 (0.6) 0.680
Nursing home resident 1 (3.4) 14 (4.1) 0.868
Physical ﬁndings
Altered mental status 4 (13.8) 29 (8.5) 0.332
Systolic blood pressure <90 mmHg 6 (20.7) 20 (5.8) 0.003
Heart rate >125 beats/min 2 (6.9) 35 (10.2) 0.568
Respiratory rate >30 breaths/min 5 (17.2) 32 (9.3) 0.172
Temperature <35 8C or 40 8C 1 (3.5) 6 (1.8) 0.518
Severity of disease
Cavitary lesion 1 (3.4) 2 (0.6) 0.098
Pleural effusion 9 (31) 52 (15.2) 0.027
ICU admission 7 (24.1) 60 (17.5) 0.371
Multilobar inﬁltrates 11 (37.9) 91 (26.5) 0.186
PSI class IV and V 25 (86.2) 182 (53.1) <0.001
CRB-65 score 2–4 6 (20.7) 54 (15.7) 0.440
Laboratory ﬁndings
PaO2 <60 mmHg 14 (48.3) 115 (33.5) 0.109
pH <7.35 3 (10.3) 10 (2.9) 0.036
BUN 30 mg/dl 13 (44.8) 69 (20.1) 0.002
Sodium <130 mmol/l 0 (0) 23 (6.7) 0.150
Platelet count,  109/l, mean (SD) 299.5 (175.7) 275.0 (123.5) 0.467
Albumin, g/dl, mean (SD) 3.27 (0.6) 3.48 (0.6) 0.088
Creatinine, mg/dl, mean (SD) 1.72 (1.3) 1.53 (1.8) 0.469
Antimicrobial administration
2 h 3 (10.3) 23 (6.7) 0.254
>2–4 h 9 (31.0) 62 (18.1)
>4–8 h 9 (31.0) 120 (35.0)
> 8 h 8 (27.6) 138 (40.2)
Antimicrobial administration in hours (time mean) 5.7 (3.1) 7.5 (4.3) 0.040
BUN, blood urea nitrogen; CAP, community-acquired pneumonia; ICU, intensive care unit; PSI, pneumonia severity index; SD, standard deviation.
Fig. 1. Propensity-adjusted risk of mortality due to community-acquired pneumonia (CAP) with 95% conﬁdence intervals, by time of ﬁrst antibiotic dosage (TFAD) upon
arrival in the emergency department, for patients hospitalized with CAP at the Veterans Hospital of Louisville, Kentucky, June 2001–March 2006.
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favorable or poor outcomes, respectively.
Antimicrobial administration within the ﬁrst 24 h of diagnosis
of CAP was not associated with any changes in the mortality rate,
as seen in Fig. 1. The outcomes of CAP may be the result of an
equation of multiple factors, and TFAD as a single factor of the
equation may not have enough weight to have an effect on the
outcomes of CAP. Due to ethical and logistic issues, studies cannot
measure the direct effect of TFAD on clinical outcomes of CAP.
Interestingly, our study patients who died received antimicrobials
signiﬁcantly earlier than survivors, suggesting that antimicrobials
as a single factor do not result in favorable outcomes. It is possible
that this counter-intuitive mortality result is due to unmeasured
factors not accounted for by the propensity model.
Waterer et al. reported the association of TFAD longer than 4 h
with an increasing mortality in a univariate analysis.14 This
association was not signiﬁcant in the multivariate analysis after
controlling for the presence of altered mental status, absence of
fever, absence of hypoxia, and increasing age.14 The latter four
factors were examined in our multivariate analysis producing
similar results to Waterer et al. and Silber et al.10,14 Conversely,
Houck et al. did not adjust for altered mental status and fever.6
Though, the strength of the study by Houck et al. is the large
sample size, the lack of adjustment for some major confounders
may have contributed to the results of decreased 30-day mortality
in patients with CAP who received antimicrobials within 4 h.6
Similar to our results, a prospective study by Bruns et al.
demonstrated that TFAD within the ﬁrst 4 h does not predict
early clinical stability, lower risk of ICU admission, or lower
mortality on day 3 in patients with moderate to severe CAP.8 Our
results of outcomes of CAP in relation to TFAD are similar to those
reported by others.10,11
Although our results demonstrated a lack of correlation
between TFAD and the clinical outcomes of CAP, we do not
recommend that antimicrobial treatment be delayed. Early
antimicrobial administration to patients with CAP is in fact a
good marker of quality of medical care.The time frames  va ry for pat ien ts having di fferent onset of the  infe
1. Patien t A had onset of pneu monia and sy mptoms much before ar
2. Patien t B had onset of  pneumonia long before arriva l to  ED  but 
3. Patien t C had onset of  pneumonia and sy mptoms just before arri
A 6 hour s TFAD of patien ts arriving to E D is not  expected to be th 
TFAD: Time of first  ant ibiotic dose.  ED:  Emergency Departmen t.  
Patien t A
Patien t B
Onset  of infection
Onset  of infection
Onset  of sympto
Fig. 2. This ﬁgure illustrates that despite patients receiving a ﬁrst antibiotic dosage at the 
onset of symptoms may vary and hence the time of ﬁrst antibiotic dosage is not the oRegardless of our study results, we consider that starting early
antimicrobial treatment is expected to contribute to an improve-
ment in the outcome of CAP. However, early TFAD from the time of
ED arrival as a single factor may be a misleading oversimpliﬁcation
since the infection and illness process begin at a variable time
before arrival in the ED (Fig. 2). The timing in CAP is a multistep
process that goes from establishment of infection, to onset of
symptoms and arrival in the ED, to TFAD. Therefore TFAD after
arrival in the ED is not a reliable objective measure of this
multistep process to control the outcomes of patients with CAP.
We suggest TFAD should be considered as an important marker of
optimal care of patients with CAP rather than as an intervention
factor to control the outcomes. Centers for Medicare and Medicaid
Service (CMS) core measures for CAP include the administration of
the initial antimicrobial within the ﬁrst 6 h of ED arrival.6,7,15 This
measure resulted in over-diagnosis of pneumonia in cases with
respiratory symptoms and the overuse of antimicrobials by ED
physicians to comply with CMS core measures for reimburse-
ment.16 The priority of the management of patients with
presumptive pneumonia should be to increase the accuracy of
the diagnosis of CAP for appropriate and timely antimicrobial
therapy. We agree with the 2007 IDSA guidelines for CAP that TFAD
should be given while the patient is in the ED.3 Fluid management,
adequacy of nutrition, functional status, immune status, and co-
morbid conditions, among others, should be considered in addition
to TFAD as factors resulting in the outcomes of CAP. Ours as well as
other studies have shown independent relationships between
outcomes of CAP and several co-morbid conditions like CHF,
neoplastic diseases, and elevated BUN at presentation.17–19
Limitations of our study include the use of an observational
database and a small sample size of patients who died. Strengths of
our study include the use of a propensity score to adjust for
confounders of a small sample size of patients who died. In
addition, our study spanned all severities of disease in adults,
including those admitted to the ICU. Another limitation of our
study is not including the Food and Drug Administration (FDA)
criteria for the diagnosis of CAP. Some of our patients may not havection and di fferen t onse t of sympto ms.  e.g.
riva l to ED
sy mptoms jus t man ifested  before  arriva l to ED
va l to ED
e sing le facto r resul ting  in th e out comes  of CAP.
Time window in ED
Arrival to ED TFAD
Patien t C
Onset  of infection  followed 
by sy mpto ms
Onset  of sympto ms
ms
CMS co re mea sur e 
TFAD 6 hour s windows
same time upon arrival in the emergency department, the process of pneumonia and
ptimal measurement and factor to predict the outcomes of pneumonia.
Fig. 3. Propensity-adjusted risk of mortality due to community-acquired pneumonia (CAP) with 95% conﬁdence intervals by time of ﬁrst antibiotic dosage (TFAD) upon arrival
in the emergency department for patients hospitalized with CAP at the Veterans Hospital of Louisville, Kentucky, June 2001–March 2006 after eliminating patients from
nursing homes and death within 48 h of hospitalization.
Fig. 4. Propensity-adjusted risk of admission to the intensive care unit with 95% conﬁdence intervals by time of ﬁrst antibiotic dosage (TFAD) upon arrival in the emergency
department for patients hospitalized with community-acquired pneumonia (CAP) at the Veterans Hospital of Louisville, Kentucky, June 2001–March 2006.
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criteria and there is a possibility that clinical improvement in some
of our patients was not due to antimicrobial therapy. Our database
does not hold data on code status or advance directives; these are
currently being implemented in our database. Our study did not
adjust for the effect of patient ‘do not resuscitate’ (DNR) on the
outcomes of CAP. We recognize that the presence of a DNR upon
arrival in the ED may have had an impact on the outcome of CAP
(Figs. 3 and 4).
In conclusion, our study did not show any association between
TFAD and the clinical outcomes of patients with CAP. Early TFAD as
a single factor does not seem to be an intervention factor to control
the outcomes of patients with CAP. Early TFAD should be
considered as an important marker of optimal patient care in
patients with CAP rather than a factor predicting the outcome.
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